|
|
Vaccine Detail
|
Recombinant Vaccinia-MUC-1 Vaccine |
| Vaccine Information |
- Vaccine Name: Recombinant Vaccinia-MUC-1 Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007018
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: MUC1
- MUC1
gene engineering:
- Preparation: The vaccine is a viral suspension of a recombinant vaccinia vector (MVA) containing DNA sequences coding for the human MUC1 antigen and interleukin-2 (IL-2) (Rochlitz et al., 2003).
- Description: This is for Breast Cancer (NCT00071942). A vaccine containing a recombinant vaccinia virus that encodes the gene for human mucin-1, a tumor-associated antigen. Upon administration, recombinant vaccinia-MUC-1 vaccine may elicit a MUC-1-specific cytotoxic T cell response against tumor cells bearing MUC-1 (NCIT_C2732).
|
| Host Response |
|
|
| References |
NCIT_C2732: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2732]
NCT00071942: [https://clinicaltrials.gov/show/NCT00071942/]
Rochlitz et al., 2003: Rochlitz C, Figlin R, Squiban P, Salzberg M, Pless M, Herrmann R, Tartour E, Zhao Y, Bizouarne N, Baudin M, Acres B. Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. The journal of gene medicine. 2003; 5(8); 690-699. [PubMed: 12898638].
|
|
